Group 1 - Aditxt's stock is experiencing a significant rise due to an update on a clinical trial from its subsidiary Pearsanta, which submitted a proposal for a Clinical Trial Translational Endpoints Research Award to the Department of Defense [1] - The proposal aims to validate a novel assay based on Pearsanta's Mitomic Technology for the early detection of ovarian cancer, which is part of the company's mission to revolutionize early cancer detection [1] - Pearsanta's president emphasized the importance of this proposal in providing a reliable, non-invasive blood test that could lead to earlier detection and more effective treatments for cancer [1] Group 2 - The trading volume of Aditxt's stock has surged, with over 97 million shares changing hands, a significant increase from the daily average of approximately 615,000 shares [2] - As of Wednesday afternoon, Aditxt's stock price has increased by 48.8% [2]
Biotech News: Why Is Aditxt (ADTX) Stock Up 49% Today?